The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

TG Therapeutic, Inc. stock soars on Briumvi success, strong Q4 results, and promising 2025 outlook. Click to discover the ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

By comparison, the rate was 0.11 and 0.14 for Aubagio, much lower than the 0.32 seen in the Tower trial of Aubagio. It’s possible that current MS studies are enrolling less sick patients, skewing the ...

Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis. Ponesimod is a ...